Oregon Cannabis Co. Facing Claims It Sickened Consumers While 2 Washington Companies Reach $618,000 Settlement Over Claims They Sent Unsolicited Texts

Top Class Actions’s website and social media posts use affiliate links. If you make a purchase using such links, we may receive a commission, but it will not result in any additional charges to you. Please review our Affiliate Link Disclosure for more information.

Curaleaf, C&G, NXNW Class Action Lawsuits Overview: 

• Who: Numerous class action lawsuits have been filed against Curaleaf Holdings, while Cannabis & Glass LLC and NXNW Retail LLC reached a $680,000 settlement with consumers. 
• Why: Curaleaf is facing allegations the company sold CBD-only products containing THC, sickening consumers, while C&G and NXNW settled to resolve claims they sent consumers unsolicited commercial texts without consent. 
• Where: The class action lawsuits were filed in Oregon and Washington federal courts, respectively. 

A wave of class action lawsuits have been filed in Oregon against cannabis company Curaleaf Holdings following claims that a mixup of CBD and THC products allegedly led to illness and deaths. 

An attorney representing Earl Jacobe claims his client experienced stroke-like symptoms after consuming what he believed to be a CBD-only product he purchased from Curaleaf, OPB reports. 

Counsel claims Jacobe and his wife had to be flown to the hospital on two separate occasions and argue the experience left him physically and mentally weakened prior to him eventually succumbing to an unrelated COVID-19 infection. 

The Oregon Liquor Control Commission has recalled hundreds of CBD-tinctures produced by Cura Cannabis Solutions, which Curaleaf acquired last year, after it was discovered they contained undisclosed THC, OPB reports. 

Plaintiff Claims She Never Consented To Receiving Promotional Text Messages

Separately, two Washington state cannabis companies announced earlier this month that they reached a $618,000 settlement to resolve claims they violated the Telephone Consumer Protection Act. 

Plaintiff Roberta Frank claimed Cannabis & Glass LLC and NXNW Retail LLC sent unsolicited and non-consented promotional texts to her phone, Law360 reports. 

Frank claims she gave her phone number to the companies while visiting their retail locations in order to be enrolled in a loyalty program; however, she claims she never consented to receiving any promotional text messages.

Despite this, Frank claims she began receiving unsolicited text messages from C&G and NXNW. 

Per the settlement agreement, claimants, which are capped at 10,300, are eligible to receive up to $60 in store credit vouchers at two storefront locations in the state. 

The case was referred to mediation back in February 2020 and took over a year of “concerted efforts” by both parties to reach a resolution, according to the proposed settlement. 

The class is composed of any individual in the state of Washington who received an unsolicited text message from either of the companies since June 22, 2015. 

Earlier this year, a class action lawsuit was filed against Hello Cannabis by a consumer who claims the company invaded their privacy and broke the law by sending promotional texts to numbers listed on the Do Not Call Registry. 

Were you sickened after consuming what you believed to be a CBD-only product purchased from Curaleaf? Did you receive unsolicited commercial texts from C&G or NXNW? Let us know in the comments! 

Frank is represented by Brian Cameron of Cameron Sutherland PLLC and Kirk D. Miller.

The Cannabis Unsolicited Texts Class Action Lawsuit is Frank v. Cannabis & Glass LLC, et al., Case No. 2:19-cv-00250, in the U.S. District Court for the Eastern District of Washington.

Read About More Class Action Lawsuits & Class Action Settlements:

• Pfizer Sold Chantix Medication With ‘Dangerously High’ Levels of Carcinogen, Class Action Alleges
• Gilead, Bristol-Myers, Pharma Companies Reach $10M Class Action Settlement After HIV Drug Conspiracy Accusations
• Class Action Lawsuit Over ‘Strength’ of Pfizer’s Robitussin Cough Syrup to Move Forward
• 2.2M At-Home COVID-19 Tests Recalled Due to False Positives in FDA’s ‘Most Serious’ Recall Level